Article
Deciphering the tumour immune microenvironment cell by cell
7 Apr 2023
Abstract excerpt
Immune checkpoint inhibitors (ICIs) have rejuvenated therapeutic approaches in oncology. Although responses tend to be durable, response rates vary in many cancer types. Thus, the identification and validation of predictive biomarkers is a key clinical priority, the answer to which is likely to lie in the tumour microenvironment (TME). A wealth of data demonstrates the huge impact of the TME on ICI response and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
